R 0016/11 of 23.03.2012
- European Case Law Identifier
- ECLI:EP:BA:2012:R001611.20120323
- Date of decision
- 23 March 2012
- Case number
- R 0016/11
- Petition for review of
- T 1710/09 2011-04-12
- Application number
- 01201913.9
- IPC class
- A61K 31/663
- Language of proceedings
- English
- Distribution
- Distributed to board chairmen and members (B)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Alendronate for use in the treatment of osteoporosis
- Applicant name
- Merck Sharp & Dohme Corp.
- Opponent name
- PLIVA, Farmaceutska Industrija Dionicko Drustvo + AWD.pharma GmbH & Co. KG
STADA Arzneimittel AG
Hexal AG + Sandoz AG
Arrow International Ltd.
betapharm Arzneimittel GmbH
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.
Gedeon Richter Plc.
Generics [UK] Ltd. et al
STADA Arzneimittel GmbH
"Interpharm" ProduktionsgmbH
BIOGARAN
Tecnimede, Sociedade Tecnico-Medicinal, S.A.
ACTAVIS GROUP - Board
- -
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 112a(2)European Patent Convention Art 113European Patent Convention Art 123(2)European Patent Convention Art 76
- Keywords
- New objection raised by the Board (no)- denial of the right to be heard (no)- petition for review clearly unallowable
- Catchword
- -
ORDER
For these reasons it is decided that:
The petition for review is rejected as clearly unallowable.